Search global stocks & ETFs...Ctrl K

Learn Mode

NTRA - Natera Inc

34

$186.36

-$10.55 (-5.358%)

At market close

$194.02

$7.66 (4.108%)

After Hours 5/15/26, 11:31 PM

Score

2.70/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

NTRA

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$26.69B

Industry

Biotechnology

EPS (TTM)

-$1.59

P/E (TTM)

0.00

Div & Yield

FCF Payout Ratio

P/S (TTM)

10.67

P/B

15.04

Diluted Shares

141.50M

Ex-Dividend

Next Earnings

08-05

Forward P/E

0.00

Payout Ratio

P/FCF (TTM)

373.23

FCF Yield

0.27%

Earnings Yield

-0.85%

52 Week Range

Score Card

Explore Scores Tab

2.70

Average

Natera Inc has grown revenue at 36.59% over the past year, which is strong growth. However, it has seen its diluted average shares outstanding increase by 5.01% over the past year, which suggests the company is diluting shareholders.

Valuation Model

Key Score

1.00

Very Bad

Management

4.00

Good

Growth

5.00

Very Good

Profitability

1.00

Very Bad

Fin. Health

2.00

Bad

Dividends

Analyst

2.00

Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-15 21:05:06

Form 10-Q

General form for quarterly financial reports under Section 13 or 15(d)

Filed on 2026-05-07 19:47:08

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-07 16:10:41

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-06 21:35:06

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-05 21:45:05

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-05 21:35:12

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-05 21:35:11

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-05 21:35:09

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-05 21:35:06

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-05 21:35:05

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-04 16:52:36

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-01 16:08:53

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$315.00

69.0%

Avg:

$257.40

38.1%

Low:

$141.40

-24.1%

(% change is relative to the current stock price: $186.36)

Analyst Recommendations

Go to Analyst Tab

4.29

Very Good

39%

Strong Buy (11)

50%

Buy (14)

11%

Hold (3)

Sell (0)

Strong Sell (0)

About

Website
https://www.natera.com/
Address
13011 Mccallen Pass, Building A Suite 100, Austin TEXAS, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1604821

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. The company is headquartered in Austin, Texas and currently employs 6,135 full-time employees. The company went IPO on 2015-07-02. The firm's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. The company has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.

IPO Date

2015-07-02

Industry

Biotechnology

Total Employees

6,138

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

NTRA - Natera Inc

34

$186.36

-$10.55 (-5.358%)

$194.02

$7.66 (4.108%)

2.70/5

Stock Unlock

Stock Profile

Score Card

Average

Insider Transactions

Market News

Form 4

Filed on 2026-05-15 21:05:06

Form 10-Q

Filed on 2026-05-07 19:47:08

Form 8-K

Filed on 2026-05-07 16:10:41

Form 4

Filed on 2026-05-06 21:35:06

Form 4

Filed on 2026-05-05 21:45:05

Form 4

Filed on 2026-05-05 21:35:12

Form 4

Filed on 2026-05-05 21:35:11

Form 4

Filed on 2026-05-05 21:35:09

Form 4

Filed on 2026-05-05 21:35:06

Form 4

Filed on 2026-05-05 21:35:05

Form 144

Filed on 2026-05-04 16:52:36

Form 144

Filed on 2026-05-01 16:08:53

Financials

Price Targets

69.0%

38.1%

-24.1%

Analyst Recommendations

About

Similar Stocks